Expanded Access for BLZ-100 (Tozuleristide)

NCT04343274 | Unknown

• 1 other identifier: BLZ-100EA
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is the Blaze Bioscience expanded access program for its investigational drug tozuleristide intended for patients with life-threatening diseases or conditions who have exhausted approved treatment options and are unable to participate in a clinical trial involving the investigational drug tozuleristide.

Interventions

Tozuleristide DRUG

Also known as: BLZ-100, Tumor Paint

Eligibility Criteria

• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Undergoing surgery for suspected or confirmed tumor
• Not eligible for current clinical trials of tozuleristide

Sponsors & Collaborators

• Blaze Bioscience Inc.: lead

MeSH Terms

Interventions

tozuleristide

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 9, 2020
• First Posted: April 13, 2020
• Last Updated: April 4, 2025

Record last verified: 2025-04